 TRACON Pharmaceuticals NASDAQ:TCON Inc said an initial independent data monitoring committee IDMC interim efficacy analysis of its ENVASARC pivotal trial is set to take place in 4Q following the enrollment of the 36th patient in the trial. The trial, which began dosing in December 2020, is a multicenter, open label, randomized, non-comparative, parallel cohort study targeting sarcoma being conducted at 30 top cancer centers in the United States and the United Kingdom. 